Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria / 中华血液学杂志
Chinese Journal of Hematology
; (12): 202-204, 2004.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-291441
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To observe the efficacy and side effect of DA/HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria (PNH).</p><p><b>METHODS</b>Eight patients with refractory and relapsed PNH were treated with DA/HA regimen chemotherapy. Three patients were treated with DA (DNR 40 mg/d, i.v.drip, the first and the second day; 20 mg/d, i.v.drip, the third day; Ara-C 100 mg/d, i.v.drip, for 5 days) and 5 patients with HA (HHT 2 - 3 mg/d, i.v.drip, for 5 days; Ara-C 100 mg/d, i.v.drip, for 5 days).</p><p><b>RESULTS</b>All the 8 patients responded well the PNH clone was diminished in five patients. Hemolysis was remitted in 6 cases. Five patients showed improvement in hematological parameters. The dosage of corticosteroid was decreased in all of them. No serious side effect was revealed.</p><p><b>CONCLUSION</b>DA/HA regimen chemotherapy was safe and effective for refractory and relapsed PNH patients.</p>
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Daunorrubicina
/
Glicosilfosfatidilinositóis
/
Citarabina
/
Tratamento Farmacológico
/
Quimioterapia Combinada
/
Harringtoninas
/
Hemoglobinúria Paroxística
Limite:
Adolescente
/
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Hematology
Ano de publicação:
2004
Tipo de documento:
Artigo